Literature DB >> 15654822

Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1.

I K Lukić1, D Grcević, N Kovacić, V Katavić, S Ivcević, I Kalajzić, A Marusić.   

Abstract

Tumour necrosis factor (TNF)-alpha, a major proinflammatory cytokine, exerts its role on bone cells through two receptors (TNFR1 and TNFR2). TNFR1, but not TNFR2, is expressed by osteoblasts and its function in bone formation in vivo is not fully understood. We compared in vivo new bone formation in TNFR1-deficient (TNFR1(-/-)) mice and wild-type mice, using two models of bone formation: intramembranous ossification following tibial marrow ablation and endochondral ossification induced by bone morphogenetic protein (BMP)-2. Intramembranous osteogenesis in TNFR1(-/-) mice did not differ from the wild-type mice either in histomorphometric parameters or mRNA expression of bone-related markers and inflammatory cytokines. During endochondral osteogenesis, TNFR1(-/-) mice formed more cartilage (at post-implantation day 9), followed by more bone and bone marrow (at day 12). mRNAs for BMP-2, -4 and -7 were increased during the endochondral differentiation sequence in TNFR1(-/-) mice. The expression of receptor activator of NF-kappa B ligand (RANKL) and receptor activator of NF-kappa B (RANK), as assessed by quantitative reverse transcription polymerase chain reaction (RT-PCR), was also increased significantly during endochondral ossification in TNFR1(-/-) mice. In conclusion, signalling through the TNFR1 seems to be a negative regulator of new tissue formation during endochondral but not intramembranous osteogenesis in an adult organism. BMPs and RANKL and its receptor RANK may be involved in the change of local environment in the absence of TNFR1 signalling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654822      PMCID: PMC1809298          DOI: 10.1111/j.1365-2249.2005.02680.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  New bone induction by demineralized bone matrix in immunosuppressed rats.

Authors:  A Marusić; I Dikić; S Vukicević; M Marusić
Journal:  Experientia       Date:  1992-08-15

Review 2.  The tumor necrosis factor ligand and receptor families.

Authors:  F Bazzoni; B Beutler
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

3.  Interleukin-1 beta enhances and tumor necrosis factor-alpha inhibits bone morphogenetic protein-2-induced alkaline phosphatase activity in MC3T3-E1 osteoblastic cells.

Authors:  T Nakase; K Takaoka; K Masuhara; K Shimizu; H Yoshikawa; T Ochi
Journal:  Bone       Date:  1997-07       Impact factor: 4.398

4.  Expression of matrix proteins during the development of mineralized tissues.

Authors:  B Sommer; M Bickel; W Hofstetter; A Wetterwald
Journal:  Bone       Date:  1996-10       Impact factor: 4.398

Review 5.  Osteocalcin: diagnostic methods and clinical applications.

Authors:  M J Power; P F Fottrell
Journal:  Crit Rev Clin Lab Sci       Date:  1991       Impact factor: 6.250

6.  Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression.

Authors:  N S Cunningham; V Paralkar; A H Reddi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption.

Authors:  L C Gerstenfeld; T J Cho; T Kon; T Aizawa; A Tsay; J Fitch; G L Barnes; D T Graves; T A Einhorn
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

8.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.

Authors:  K Pfeffer; T Matsuyama; T M Kündig; A Wakeham; K Kishihara; A Shahinian; K Wiegmann; P S Ohashi; M Krönke; T W Mak
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Inhibition by tumor necrosis factor of induction of ectopic bone formation by osteosarcoma-derived bone-inducing substance.

Authors:  H Yoshikawa; J Hashimoto; K Masuhara; K Takaoka; K Ono
Journal:  Bone       Date:  1988       Impact factor: 4.398

10.  RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.

Authors:  Ping Li; Edward M Schwarz; Regis J O'Keefe; Lin Ma; Brendan F Boyce; Lianping Xing
Journal:  J Bone Miner Res       Date:  2004-02       Impact factor: 6.741

View more
  5 in total

Review 1.  Mechanisms of pathologic new bone formation.

Authors:  Kurt de Vlam; Rik J U Lories; Frank P Luyten
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 2.  Mechanical modulation of osteochondroprogenitor cell fate.

Authors:  Melissa L Knothe Tate; Thomas D Falls; Sarah H McBride; Radhika Atit; Ulf R Knothe
Journal:  Int J Biochem Cell Biol       Date:  2008-05-24       Impact factor: 5.085

3.  Direct bone formation during distraction osteogenesis does not require TNFalpha receptors and elevated serum TNFalpha fails to inhibit bone formation in TNFR1 deficient mice.

Authors:  Elizabeth C Wahl; James Aronson; Lichu Liu; Robert A Skinner; Mike J Miller; Gael E Cockrell; John L Fowlkes; Kathryn M Thrailkill; Robert C Bunn; Martin J J Ronis; Charles K Lumpkin
Journal:  Bone       Date:  2009-09-17       Impact factor: 4.398

4.  Inhibition of apoptosis signal-regulating kinase 1 enhances endochondral bone formation by increasing chondrocyte survival.

Authors:  G J Eaton; Q-S Zhang; C Diallo; A Matsuzawa; H Ichijo; M J Steinbeck; T A Freeman
Journal:  Cell Death Dis       Date:  2014-11-13       Impact factor: 8.469

5.  Genome-wide analyses of gene expression during mouse endochondral ossification.

Authors:  Claudine G James; Lee-Anne Stanton; Hanga Agoston; Veronica Ulici; T Michael Underhill; Frank Beier
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.